Clinical Trial Update: 18F-DCFPyL PET/CT in Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the PSMA PET imaging agent 18F-DCFPyL for hepatocellular carcinoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• 18F-DCFPyL (DCFPyL radiotracer for PSMA imaging)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-08-28